Cell type-associated traits map for the [FetalKidney_Smooth muscle cell][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [FetalKidney_Smooth muscle cell]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
Age At Menarche | Age At Menarche | ETC | Perry | 2014 | NA | 182413 | 1.00e-3 | 2.54e-2 |
Age At Menarche | Age At Menarche | ETC | Perry | 2014 | NA | 182413 | 1.00e-4 | 3.85e-2 |
Birth Weight | Birth Weight | MTC | Horikoshi | 2013 | NA | 26836 | 5.00e-2 | 2.04e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-2 | 2.87e-2 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 5.00e-2 | 1.35e-3 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-2 | 1.19e-2 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 1.16e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-3 | 4.21e-2 |
Insomnia | Insomnia | MTC | Hammerschlag | 2017 | 12863 | 40776 | 1.00e-3 | 1.02e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 5.00e-2 | 3.11e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-2 | 2.07e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-3 | 1.50e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-4 | 4.86e-3 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-5 | 1.54e-2 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 1.00e-3 | 3.16e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 4.79e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 1.00e-2 | 4.53e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 5.00e-2 | 1.60e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-2 | 2.56e-2 |
Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 1.00e-3 | 1.29e-2 |
Anthropometric Extremes | Obesity Class 1 | MTC | Berndt | 2013 | 32858 | 65840 | 5.00e-2 | 3.04e-3 |
Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 5.00e-2 | 1.57e-2 |
Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 1.00e-2 | 3.05e-3 |
Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 1.00e-3 | 1.86e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 4.07e-2 |
Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 1.36e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 1.00e-3 | 9.48e-3 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-3 | 3.16e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Men | MTC | Randall | 2013 | NA | 34629 | 1.00e-3 | 1.66e-4 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 5.00e-2 | 6.33e-3 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 1.00e-2 | 3.67e-2 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 1.00e-4 | 3.61e-2 |
BMI Age Stratified | BMI Women Age Under 50 | MTC | Winkler | 2015 | NA | 60654 | 1.00e-4 | 2.60e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 1.00e-4 | 4.00e-3 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 8.00e-3 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 3.63e-2 |
BMI Physical Activity Interaction | BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 4.09e-2 |
BMI Physical Activity Interaction | BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 7.13e-3 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.90e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.92e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.94e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 3.90e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.56e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.30e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 4.14e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 4.69e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.34e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.68e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 6.95e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 4.00e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.29e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.13e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.37e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 5.35e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 4.08e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 8.88e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.37e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.57e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.28e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 2.37e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 7.12e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 2.63e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.12e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 1.56e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 5.00e-2 | 4.47e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-3 | 1.33e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-2 | 3.45e-2 |
Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 1.00e-2 | 4.01e-2 |
Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 3.46e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 7.12e-3 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 3640 | 1.00e-3 | 2.30e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 3.14e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 1.00e-3 | 2.88e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 2.72e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7381 | 1.00e-2 | 5.55e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.75e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-2 | 2.92e-2 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 2.27e-2 |
Facial Shape | Mod11 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.57e-2 |
Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.45e-2 |
Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.03e-2 |
Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.64e-2 |
Facial Shape | Mod22 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.90e-2 |
Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.38e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.92e-2 |
Facial Shape | Mod42 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.68e-2 |
Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.50e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 1.01e-2 |
Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 5.00e-2 | 3.54e-2 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.03e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.22e-2 |
Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-2 | 1.81e-2 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 5.00e-2 | 4.37e-2 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 2.28e-3 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-2 | 6.49e-3 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-3 | 2.58e-2 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 1.41e-2 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-2 | 2.03e-2 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 1.75e-2 |
Lean Body Mass | Appendicular Lean Mass | MTC | Zillikens | 2017 | NA | 28330 | 5.00e-2 | 2.34e-2 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 2.93e-2 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 1.00e-3 | 1.30e-2 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 2.10e-2 |
Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 5.61e-3 |
Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 2.97e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 3.28e-2 |
Waist Format 1 | Waist Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 2.97e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 6.04e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 6.65e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 4.51e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 8.55e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 1.11e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 3.80e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 4.23e-2 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 4.50e-3 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 1.04e-2 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 2.11e-2 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 1.01e-2 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 2.79e-3 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 4.04e-3 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 4.90e-2 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 2.70e-3 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 2.00e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 4.08e-3 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-5 | 1.96e-2 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.78e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-3 | 3.91e-2 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-2 | 3.54e-2 |
Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 1.00e-2 | 1.72e-2 |
Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 1.00e-4 | 2.21e-2 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 2.31e-2 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 6.14e-3 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 1.74e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 2.63e-2 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 3.97e-2 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 2.18e-2 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 5.00e-2 | 1.27e-2 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-2 | 1.58e-2 |
Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 5.00e-2 | 4.33e-3 |
Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 1.00e-3 | 3.36e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-4 | 2.30e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 5.00e-2 | 4.52e-2 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 1.00e-5 | 4.09e-2 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-2 | 3.20e-2 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-4 | 4.69e-2 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-5 | 4.08e-2 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 5.00e-2 | 4.69e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 1.47e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 1.82e-2 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.45e-2 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.73e-2 |
Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.55e-2 |
Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.62e-2 |
Hippocampal volume | Hippocampal subfield CA3 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.67e-2 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-3 | 1.39e-2 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-2 | 4.31e-2 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-4 | 2.30e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-2 | 3.09e-3 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-3 | 1.61e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 4.52e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 5.19e-3 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 4.30e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-3 | 3.74e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 2.97e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-4 | 2.97e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-2 | 2.94e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-3 | 3.65e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-4 | 4.08e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-5 | 3.56e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-4 | 4.82e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-5 | 1.52e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-3 | 2.49e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-4 | 1.11e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-5 | 8.51e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 1.31e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 2.51e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 1.24e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-5 | 2.71e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-3 | 1.93e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-4 | 3.94e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-5 | 2.55e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-2 | 4.38e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-3 | 1.70e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 1.48e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 4.33e-2 |
Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 1.00e-2 | 4.16e-2 |
Lung function | Lung function (forced vital capacity) variance | ETC | Wang H | 2019 | NA | 317,222 | 1.00e-2 | 3.17e-2 |
Heel bone mineral Density | Heel bone mineral density variance | ETC | Wang H | 2019 | NA | 197,261 | 1.00e-3 | 3.72e-2 |
BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 1.00e-4 | 4.37e-2 |
BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-3 | 4.80e-2 |
BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 5.00e-2 | 3.46e-2 |
BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 5.00e-2 | 6.70e-3 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 4.98e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-2 | 7.56e-3 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.65e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.54e-2 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-2 | 9.34e-4 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-3 | 5.79e-4 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-4 | 4.52e-3 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-5 | 3.99e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 2.04e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 7.96e-4 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 1.57e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 4.46e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 1.08e-2 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-5 | 2.71e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-2 | 4.87e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-3 | 3.17e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-4 | 1.47e-2 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 5.00e-2 | 1.07e-2 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 1.00e-2 | 2.85e-2 |
COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 5.00e-2 | 2.95e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.